



Research Journal of Pharmaceutical, Biological and Chemical Sciences

The Role Of Computer Aided Drug Design In Drug Discovery.

Neelam Yadav, Piyush Yadav*, and Shivanand Yadav.

Prasad Institute Of Technology, Department Of Pharmacy, Jaunpur – 222001, Uttar Pradesh, India.

ABSTRACT

Computer-assisted drug design is a relatively new and highly effective technology in the modern arena. Computer Aided Drug Design (CADD) technologies are now widely used in nanotechnology, molecular biology, and biochemistry, among other fields. The key advantage of the CADD is its low cost. Drug development and research CADD, Grid computing, window-based general PBPK/PD modelling software, and PKUDDS are all examples of software used in CADD. APIS, JAVA, Perl and Python, CADD, and software including software libraries are all used in structure based drug design. CADD employs a variety of approaches. Molecular docking, visualisation, homology, molecular dynamics, energy minimization QSAR, for example. Computer-assisted medication design has applications in cancer, transportation, and other fields. data collection and storage of organics and biologicals, medication delivery to particular sites in the body This technique focuses on conformational characteristics and energetics of tiny molecules, DNA cleavage, and molecular diagnostics based on fluorescences.

Keywords: Computer-aided drug design; Pharmacophore; QSAR; Virtual screening.

<https://doi.org/10.33887/rjpbcs/2022.13.6.7>

**Corresponding author*

INTRODUCTION


Computer aided drug design (CADD) is a set of tools and procedures that aid in the various stages of drug design, lowering the cost of research and development and shortening the time it takes to produce a medicine. Drug discovery and development is a lengthy, difficult, expensive, and high-risk process with few parallels in the commercial sector. This is why, in order to speed up the process, computer-aided drug design (CADD) technologies are frequently used in the pharmaceutical business. Using computational techniques in the lead optimization phase of drug development saves a lot of money. The big pharmaceutical corporations have made significant investments in routine ultra-High Throughput Screening (uHTS) of large numbers of drug-like compounds. Parallel to this, virtual screening is becoming more used in medication design and optimization. Recent advances in DNA microarray tests that look at thousands of genes linked in an illness can be utilised to learn more about the condition in depth. Empirical molecular mechanics, quantum mechanics, and, more recently, statistical mechanics are among the theoretical techniques. This newest advancement has made it possible to include explicit solvent effects. The availability of high-quality computer graphics, which is mostly supported on workstations, underpins all of this effort.

METHODOLOGY

In the early 1970s, structural biology was used to change the biological function of insulin 6 and to guide the production of human hemoglobin ligands, laying the groundwork for CADD. X-ray crystallography was prohibitively expensive and time-consuming at the time, making it unsuitable for large-scale screening in industrial facilities. New tools have arisen over time, including as comparative modelling based on natural structural homologues, and have begun to be used in lead design. Advances in combinatorial chemistry, high-throughput screening technologies, and computational infrastructures, in combination with advances in combinatorial chemistry, high-throughput screening technologies, and computational infrastructures, have rapidly bridged the gap between theoretical modelling and medicinal chemistry.

Drug Discovery Process

Therapeutic discovery is a set of procedures that, when followed, result in the identification of drug molecules that are effective in treating or controlling disease targets. It all starts with a vast number of chemical compounds being screened to find the best disease targets. It necessitates knowledge of the drug receptor's structure so that drug molecules can be tailored to the binding site.



Candidate Drug Discovery

- Selection of Therapeutic Target
- Lead Discovery
- Lead Optimization

Pre clinical and clinical trials to evaluate the safety, efficacy and adverse effects of the drug

- ❖ Animal Studies
- ❖ Clinical Trials

In general, new medication research and pre-clinical development take 3-6 years. Clinical studies might take up to ten years or more before a product is approved for sale. [10] A successful medicine takes 12-15 years to develop and costs more than \$1.3 billion to commercialise. [11] On average, 250 compounds are chosen for preclinical trials from a pool of 5000-10000 screened compounds. Only five of them make it into clinical trials, and only one is approved by the FDA following a thorough assessment of the newly discovered medicine.

Software used in drugs discovery

Grid computing applications, window-based generic PBPK/PD modelling software, PKUDDS for structure-based drug design, APIS, JAVA, Perl and Python, CADD, and software incorporating software libraries are among the software programmes.




Figure: Drug Discovery.

Visualization

Tools like as Rasmol, VMD, Molscript, and Raster 3D are used to optimise ligand or chemical compound and target molecule interactions. Rasmol, a computer application for molecular graphics, is used to represent and explore biological macromolecule structures. Programs for homology and homology modelling Because most medication targets are proteins, it's critical to understand their three-dimensional structures. The human body is thought to have between five and one million proteins, yet only a small fraction of these have a 3D structure. Protein 3D structure is predicted via homology modeling¹⁵. Homology modelling is nothing more than a search for pharmacological analogues based on similarities. The process begins with a promising therapeutic compound. Molecular modeling¹⁶ is the study of numerically modelling molecular structures and simulating their behaviour using quantum and classical physics equations. For similarity searches and sequence matching, there are two computational tools: BLAST and FASTA, as well as numerous sequence alignments. Clastal W Visualization-

Molecular modeling

Molecular modelling is a broad phrase that refers to a variety of molecular graphics and computational chemistry approaches for creating, displaying, manipulating, simulating, and analysing molecular structures as well as calculating their attributes. To a chemical physicist, molecular modelling entails conducting a high-quality quantum mechanical calculation on the structure using a supercomputer; to a medicinal chemist, molecular modelling entails executing a high-quality quantum mechanical calculation on the structure using a supercomputer. The ability to visualise molecular characteristics is a crucial part of molecular modelling.


Molecular graphics

The core of a modelling system is molecular graphics, which allows for the viewing of molecular structure and properties. Graphic packages translate the data provided by molecular modelling into a visual depiction on the computer screen. These images can be presented in a variety of ways, including space fill, CPK (Corey-Pauling-Koltum), stick, mesh, ball and stick, ribbon, and colour scheme with visual aids. Ribbon presentation is utilised for bigger molecules like nucleic acids and proteins because it allows the structure to be examined from numerous angles and fitted to its target spot.


Molecular computational chemistry

Computational chemistry programmes can be used to calculate the molecular characteristics of a certain structure. Molecular mechanics or quantum mechanics are used in computational chemistry.


Structure-based drug design (SBDD)




Benzoic acid stick model




Benzoic acid cylindrical bonds



Benzoic acid ball and stick model




Benzoic acid wire and frame model



Benzoic acid space filling model

Structure-based drug design (SBDD)

The knowledge gained from a 3D macromolecule structure's binding site is used in SBDD to design and evaluate ligands based on their predicted interactions with the protein binding site (Lavecchia and Di Giovanni 2013; Thus, identifying a valid drug target and obtaining its structural information are the first crucial steps in SBDD. The employment of X-ray crystallography, nuclear magnetic resonance (NMR), cryo-electron microscopy (EM), homology modelling, and molecular dynamics in structural and computational biology research aided in the development of protein structures.



Software s And Its Application in Drug Design -

S.NO.	SOFTWARE	APPLICATION OF DRUG DESIGN
1	Sculpt	Building of 3D Structures Superimpose flexible molecule Through conformational analysis ,identify Pharmacophore Visualize purpose of Drug.
2	Accord for Access	Interface for visualization of chemical structure access to Over 20,000 reactions.
3	Gauss view Gaussian 97w	Graphical Interface to Gaussian molecule building advance visualization graphically display molecular orbital electron density, surfaces,electrostatic potential structures atomic charges ionization potential dipole movement.
4	Camel eon	predictive tool -to generate DNA and protein as per your own Sequence in 3D to correlate sequence with residue properties - gives structural characteristics.
5	Amber V4.1	Molecular modeling and molecular simulation studies .It uncovers Loops. Interactions and active sites and examines similarity with Pharmacophore.
6	Tsar	QSAR analysis - data import ,data calculation , analysis and Interpretation automatically.
7	Asp	Predicts binding affinity of a potential drug where structure of binding site is unknown.
8	Cobra	Automated conformational analysis to generate a set of low energy confirmations.
9	Anaconda	Identifies pharmacophore by visual quantitative comparison of molecular surface.

Homology and homology modeling programs

Because most medication targets are proteins, it's critical to understand their three-dimensional structures. The human body is thought to have between five and one million proteins, yet only a small fraction of these have a 3D structure. Protein 3D structure is predicted via homology modeling¹⁵. Homology modelling is nothing more than a search for pharmacological analogues based on similarities. The process begins with a promising therapeutic compound. Molecular modeling¹⁶ is the study of numerically modelling molecular structures and simulating their behaviour using quantum and classical physics equations. For similarity searches and sequence alignment, there are two computational tools: BLAST and FASTA, and ClastalW and ClastalX for multiple sequence alignments.

Docking- Molecular dynamics

The study of molecule mobility is known as molecular dynamics. Every molecule has its unique vibration frequency. It can oscillate from one to two to zero, with the molecule having the most potential energy at one and two and the least at zero. [18]

Energy minimization

It's also known as energy optimization or geometry optimization, and it's used to figure out how molecules and solids should be in equilibrium. We can only get a final state of the system that corresponds to a minimum of potential energy using this strategy. A molecule with the least energy state, i.e. zero energy state, can be obtained through energy minimization. In this state, the molecules are in a state of equilibrium. GAMESS Ghemical PS13 TINKER is an energy-saving tool. For quantum mechanical calculations, Ghemical or PS13 can be employed. If proteins are employed, a tool like PyMol can be used to find ligand binding pockets, and the DeepView PDB viewer can be used to look at the protein's amino acid sequences. Open Babel may be beneficial or even essential to interconvert.

Docking is a method in molecular modelling that predicts the preferred orientation of one molecule to another when they are linked together to form a stable Complex. The binding of a ligand to its receptor or target protein is referred to as docking. Docking is a technique for identifying and optimising drug candidates by studying and simulating the molecular interactions between the ligand and the target macromolecules. Multiple ligand conformations and orientations are formed during docking, and the most suited ones are chosen. ArgusDock DOCK FRED eHITS AutoDock FTDock are some of the docking tools that are now available.

Application of computer in drug design-

1. Target Enzyme
2. Drug Transport
3. Structure Anticancer agent
4. determination of protein
5. Biochemical Transformation
6. Molecular similarity
7. Molecular dissimilarity

CONCLUSION

CADD is now widely regarded as a viable option to high-throughput screening and a useful addition to it. The creation of high-quality datasets and design libraries that can be optimized for molecular diversity or similarity has resulted from the quest for new molecular entities. On the other hand, breakthroughs in molecular docking methods, paired with advances in computational infrastructure, are allowing for fast increases in screening throughput. Put. Distributed computing is gaining appeal for large-scale screening operations, fueled by increasingly powerful technologies. These developments, when combined with coordinated efforts to create more detailed physical models such as solubility and protein salvation, will allow for the first time the entire promise of lead discovery by design to be realized [1-21].

REFERENCES

- [1] Bing Wu et al. In silico prediction of nuclear hormone receptors for organic pollutants by homology modeling and molecular docking *Toxicology Letters* 191,69-73,2009.
- [2] Jadhav Ramulu and P. Goverdhan. *pharma tutor*. Computer Aided Drug Design an Emerging Tool for Research and Drug Development . PHARMATUTOR-1101. Page 1-16.
- [3] Itztein MV, Wu WY, Kok GB (1993) Rational design of potent sialidase- based inhibitors of influenza virus replication *Nature* 363:418-432.
- [4] Valentina IK (2010) Molecular modeling. *Chem Eur J* 2 (2):422-424.
- [5] Ilango KV (2010) Molecular graphics *Der Pharma Chemica* 2(2):422-426.
- [6] Kitchen D B, Decornez H, Furr J R, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. *Nature reviews in drug discovery*, 2004; 3: 935-949.
- [7] DiMasi J A, Grabowski H G. The cost of biopharmaceutical R&D: is biotech different? *Managerial and Decision Economics*, 2007; 28: 469-479.
- [8] Duprat AF, Huynh T, Dreyfus G (1998) Toward a principled methodology for neural network design and performance evaluation in QSAR: Application to the prediction of Log P. *J Chem Inf Comput Sci* 38(4): 586-594.
- [9] LS. Haworth, A.H. Elcock, A. Rodger and W.G. Richards. J. Sequence selective binding to the DNA major groove: tris (1,10 phenanthroline) metal complexes binding to poly(dGdC) and poly (dAdT). *Biomol. Struct. and Dynamics* 9,23 (1991).
- [10] Bioreductive anti-cancer drugs. W.G. Richards and C.A. Reynolds, in *Theoretical Biochemistry and Molecular Biophysics* (eds. D.L. Beveridge & R Lavery), Adenine Press, Schenectady (1990).
- [11] Free energy calculations of pharmaceutically important properties. P.M. King C.A. Reynolds, J.W. &ex, G.A. Worth and W.G. Richards. *Mol. Simulation* 5,265(1990).
- [12] W. G. RICHARDS, 1994. Computer-aided drug design. *Pure & Appl. Chem.*, Vol.66, No. 8, pp. 1589-1596.
- [13] A theoretical study of the structure of big endothelin. M.C. Menziani, M. Cocchi, P.G. De Benedetti, R.G. Gilbert, W.G. Richards, M. Zamai, V.R. Caiolfa. *J.ChimPhys.* 88,2687 (1991).
- [14] A linear molecular similarity index. C.A. Reynolds, C. Burt and W.G. Richards. *Quant. Struct.Act. Relat.* 11, 34 (1992).
- [15] Chun Meng Song et. al., 2009. Recent advances in computer-aided drug design. *Briefings in bioinformatics*. VOL 10. NO 5. pp.579-591.
- [16] Jorgensen, W.L. et al. The many roles of computation in drug discovery. *Science* 303, 1813- 1818, 2004.
- [17] Hajduk, P.J. et al. Predicting protein druggability. *Drug Discovery Today* 101675-1682, 2005.
- [18] Perdo and Hui lei, 2010. A systematic review on CADD: Docking and Scoring *JMPI*. Page 47-51.
- [19] Werner J. Geldenhuys et al. Optimizing the use of open-source software applications in drug discovery, Volume 11, Number 3/4 February 2006.
- [20] Hou T. Xu X. Recent development and Application of Virtual Screening in Drug Discovery: An Overview. *Current Pharmaceutical Design*, 2004; 10: 1011-1033.
- [21] Leeson P D, Davis A M, Steele J. Drug-like properties: Guiding principles for design – or chemical prejudice? *Drug Discovery Today: Technologies*, 2004; 1(3): 189-195.